Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × famitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 7 Breast Neoplasms 5 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Melanoma 2 Cervical Cancer Metastatic 2 Thyroid Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Neoadjuvant Therapy 1 NSCLC 1 Esophageal Squamous Cell Carcinoma 1 Disease Progression 1 Carcinoma, Non-Small-Cell Lung 1 BRCA-Mutated Breast Carcinoma 1

Interventions

Pemetrexed 9 Drug Therapy 9 osimertinib 7 Radiotherapy 6 Carboplatin 6 anlotinib 5 Radiosurgery 5 Gefitinib 4 Docetaxel 4 Cisplatin 4 tislelizumab 3 pembrolizumab 3 icotinib 3 aflutinib 3 Vinorelbine 3 Paclitaxel 3 Gemcitabine 3 Erlotinib Hydrochloride 3 toripalimab 2 dacomitinib 2 camrelizumab 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Liquid Biopsy 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05005468 2021-08-13

CAMFA-L

Shanghai Chest Hospital

Phase 2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡